eligibility_summary
Adults >=18 with newly diagnosed DLBCL, cfDNA+ pre-treatment (mut/CNV/IgH fusion/IG clonality), CMR after 6 R-CHOP, life expectancy >6 mo, consent. Exclude: prior auto-SCT, other malignancy (except basal cell/in situ cervical), uncontrolled CV/coag/infection, primary CNS lymphoma, noncompliance/psychiatric, pregnant/lactating, HBV: include only after seroconversion, HIV+.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Interventions: plasma cfDNA–guided therapy after 6 cycles of R-CHOP-like in DLBCL patients in complete metabolic remission. Diagnostic: cfDNA assay (liquid biopsy) detecting tumor ctDNA (point mutations, CNVs, IgH fusions, IG clonality) to guide treatment. Therapeutics: rituximab monotherapy (375 mg/m2 q3w ×2), a chimeric anti-CD20 monoclonal antibody mediating complement-dependent cytotoxicity, ADCC, and apoptosis, or continuation of R-CHOP-like ×2 cycles—cyclophosphamide (alkylating agent), doxorubicin (anthracycline/topoisomerase II inhibitor), vincristine (vinca alkaloid microtubule inhibitor), prednisone (glucocorticoid). Targets: CD20+ malignant B cells, DNA replication/repair (alkylation, topo II), mitotic spindle (tubulin), glucocorticoid receptor–mediated lymphocyte apoptosis, cfDNA captures tumor genomic MRD.